Patents by Inventor Xusheng Ma

Xusheng Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant nucleic acid of Seneca valley virus, recombinant vaccine strain and preparation method and use thereof
    Patent number: 11883482
    Abstract: The disclosure provides a recombinant nucleic acid of Seneca valley virus, a recombinant vaccine strain and preparation method and use thereof, and relates to the technical field of genetic engineering. The disclosure provides the recombinant nucleic acid of Seneca valley virus, recombinant Seneca valley virus comprising the recombinant nucleic acid, recombinant Seneca valley virus encoded by the recombinant nucleic acid, recombinant Seneca valley virus vaccine strain comprising the recombinant Seneca valley virus and preparation method and use thereof. According to the disclosure, a vaccine strain characterized by high antigen production capacity, remarkably reduced pathogenicity (even having no pathogenicity to pigs), strong antibody induction activity, high immune protection rate is prepared. The vaccine strain remarkably improves the biological safety and can be used for preventing and controlling Seneca valley virus in China and the neighboring countries.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: January 30, 2024
    Inventors: Haixue Zheng, Fan Yang, Zixiang Zhu, Weijun Cao, Hong Tian, Keshan Zhang, Ting Wei, Min Zheng, Wei Zhang, Wen Dang, Xusheng Ma, Dan Li, Yi Ru, Jijun He, Jianhong Guo, Xiangtao Liu
  • Use of compound aprepitant in preparation of drug for preventing or treating African swine fever (ASF)
    Patent number: 11883411
    Abstract: The present disclosure belongs to the technical field of African swine fever (ASF) treatment, in particular to use of a compound aprepitant in prevention or treatment of the ASF. In the present disclosure, it is found that the compound aprepitant can significantly inhibit replication of an African swine fever virus (ASFV); in addition, it is found that the aprepitant inhibits transcription and protein expression of D1133L, and reduces transcription and protein expression levels of p30 and p72, preventing virus invasion on host cells. Therefore, the compound aprepitant can be used to inhibit early and late infection of the ASFV. Accordingly, the compound aprepitant can be used to prevent or treat the ASF.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: January 30, 2024
    Assignee: LANZHOU VETERINARY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Keshan Zhang, Haixue Zheng, Huimei Cui, Bo Yang, Hong Tian, Zixiang Zhu, Tao Feng, Fan Yang, Weijun Cao, Xusheng Ma, Yi Ru, Jianhong Guo, Xiangtao Liu
  • USE OF COMPOUND APREPITANT IN PREPARATION OF DRUG FOR PREVENTING OR TREATING AFRICAN SWINE FEVER (ASF)
    Publication number: 20230270747
    Abstract: The present disclosure belongs to the technical field of African swine fever (ASF) treatment, in particular to use of a compound aprepitant in prevention or treatment of the ASF. In the present disclosure, it is found that the compound aprepitant can significantly inhibit replication of an African swine fever virus (ASFV); in addition, it is found that the aprepitant inhibits transcription and protein expression of D1133L, and reduces transcription and protein expression levels of p30 and p72, preventing virus invasion on host cells. Therefore, the compound aprepitant can be used to inhibit early and late infection of the ASFV. Accordingly, the compound aprepitant can be used to prevent or treat the ASF.
    Type: Application
    Filed: August 25, 2022
    Publication date: August 31, 2023
    Applicant: LANZHOU VETERINARY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Keshan ZHANG, Haixue ZHENG, Huimei CUI, Bo YANG, Hong TIAN, Zixiang ZHU, Tao FENG, Fan YANG, Weijun CAO, Xusheng MA, Yi RU, Jianhong GUO, Xiangtao LIU
  • Recombinant Nucleic Acid of Seneca Valley Virus, Recombinant Vaccine Strain and Preparation Method and Use Thereof
    Publication number: 20220031832
    Abstract: The disclosure provides a recombinant nucleic acid of Seneca valley virus, a recombinant vaccine strain and preparation method and use thereof, and relates to the technical field of genetic engineering. The disclosure provides the recombinant nucleic acid of Seneca valley virus, recombinant Seneca valley virus comprising the recombinant nucleic acid, recombinant Seneca valley virus encoded by the recombinant nucleic acid, recombinant Seneca valley virus vaccine strain comprising the recombinant Seneca valley virus and preparation method and use thereof. According to the disclosure, a vaccine strain characterized by high antigen production capacity, remarkably reduced pathogenicity (even having no pathogenicity to pigs), strong antibody induction activity, high immune protection rate is prepared. The vaccine strain remarkably improves the biological safety and can be used for preventing and controlling Seneca valley virus in China and the neighboring countries.
    Type: Application
    Filed: May 24, 2021
    Publication date: February 3, 2022
    Applicant: Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
    Inventors: Haixue Zheng, Fan Yang, Zixiang Zhu, Weijun Cao, Hong Tian, Keshan Zhang, Ting Wei, Min Zheng, Wei Zhang, Wen Dang, Xusheng Ma, Dan Li, Yi Ru, Jijun He, Jianhong Guo, Xiangtao Liu